Risk evaluation and monitoring in multiple sclerosis therapeutics

por Clanet, Michel C, Wolinsky, Jerry S, Ashton, Raymond J, Hartung, Hans-Peter, Reingold, Stephen C
Publicado 2014

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability

por Wolinsky, Jerry S, Engmann, Natalie J, Pei, Jinglan, Pradhan, Ashish, Markowitz, Clyde, Fox, Edward J
Publicado 2020

The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis

por Ben-Zacharia, Aliza Bitton, Janal, Malvin N., Brody, Abraham A., Wolinsky, Jerry, Lublin, Fred, Cutter, Gary
Publicado 2021

Regional Gray Matter Atrophy in Relapsing Remitting Multiple Sclerosis: Baseline Analysis of Multi-Center Data

por Datta, Sushmita, Staewen, Terrell D., Cofield, Stacy S., Cutter, Gary R., Lublin, Fred D., Wolinsky, Jerry S., Narayana, Ponnada A.
Publicado 2015

Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions

por Elliott, Colm, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Wei, Wei, Belachew, Shibeshih, Arnold, Douglas L
Publicado 2018

Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials

por Giovannoni, Gavin, Kappos, Ludwig, de Seze, Jerome, Hauser, Stephen L., Overell, James, Koendgen, Harold, Manfrini, Marianna, Wang, Qing, Wolinsky, Jerry S.
Publicado 2021

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

por Fox, Edward J, Markowitz, Clyde, Applebee, Angela, Montalban, Xavier, Wolinsky, Jerry S, Belachew, Shibeshih, Fiore, Damian, Pei, Jinglan, Musch, Bruno, Giovannoni, Gavin
Publicado 2018

Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set

por Koch, Marcus W., Cutter, Gary R., Giovannoni, Gavin, Uitdehaag, Bernard M.J., Wolinsky, Jerry S., Davis, Mat D., Steinerman, Joshua R., Knappertz, Volker
Publicado 2017

Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial

por Weinstock-Guttman, Bianca, Bermel, Robert, Cutter, Gary, Freedman, Mark S, Leist, Thomas P, Ma, Xiaoye, Kile, Deidre, Musch, Bruno, Reder, Anthony T, Wolinsky, Jerry S
Publicado 2021

Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study()

por Narayana, Ponnada A., Govindarajan, Koushik A., Goel, Priya, Datta, Sushmita, Lincoln, John A., Cofield, Stacy S., Cutter, Gary R., Lublin, Fred D., Wolinsky, Jerry S.
Publicado 2012

Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis

por Hauser, Stephen L., Kappos, Ludwig, Montalban, Xavier, Craveiro, Licinio, Chognot, Cathy, Hughes, Richard, Koendgen, Harold, Pasquarelli, Noemi, Pradhan, Ashish, Prajapati, Kalpesh, Wolinsky, Jerry S.
Publicado 2021

The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies

por Freedman, Mark S, Wolinsky, Jerry S, Comi, Giancarlo, Kappos, Ludwig, Olsson, Tomas P, Miller, Aaron E, Thangavelu, Karthinathan, Benamor, Myriam, Truffinet, Philippe, O’Connor, Paul W
Publicado 2017

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial

por Wolinsky, Jerry S., Montalban, Xavier, Hauser, Stephen L., Giovannoni, Gavin, Vermersch, Patrick, Bernasconi, Corrado, Deol‐Bhullar, Gurpreet, Garren, Hideki, Chin, Peter, Belachew, Shibeshih, Kappos, Ludwig
Publicado 2018

Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis

por Elliott, Colm, Belachew, Shibeshih, Wolinsky, Jerry S, Hauser, Stephen L, Kappos, Ludwig, Barkhof, Frederik, Bernasconi, Corrado, Fecker, Julian, Model, Fabian, Wei, Wei, Arnold, Douglas L
Publicado 2019

Lymphocyte counts and infection rates: Long-term fingolimod treatment in primary progressive MS

por Fox, Edward J., Lublin, Fred D., Wolinsky, Jerry S., Cohen, Jeffrey A., Williams, Ian M., Meng, Xiangyi, Ziehn, Marina, Kolodny, Scott, Cree, Bruce A.C.
Publicado 2019

Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Ana...

por Kappos, Ludwig, Wolinsky, Jerry S., Giovannoni, Gavin, Arnold, Douglas L., Wang, Qing, Bernasconi, Corrado, Model, Fabian, Koendgen, Harold, Manfrini, Marianna, Belachew, Shibeshih, Hauser, Stephen L.
Publicado 2020

Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis

por Turner, Benjamin, Cree, Bruce A. C., Kappos, Ludwig, Montalban, Xavier, Papeix, Caroline, Wolinsky, Jerry S., Buffels, Regine, Fiore, Damian, Garren, Hideki, Han, Jian, Hauser, Stephen L.
Publicado 2019

Relapse recovery in relapsing–remitting multiple sclerosis: An analysis of the CombiRx dataset

por Koch, Marcus W, Moral, Ester, Brieva, Luis, Mostert, Jop, Strijbis, Eva MM, Comtois, Jacynthe, Repovic, Pavle, Bowen, James D, Wolinsky, Jerry S, Lublin, Fred D, Cutter, Gary
Publicado 2023

Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis

por Miller, Aaron E, O’Connor, Paul, Wolinsky, Jerry S, Confavreux, Christian, Kappos, Ludwig, Olsson, Tomas P, Truffinet, Philippe, Wang, Lin, D’Castro, Laura, Comi, Giancarlo, Freedman, Mark S
Publicado 2012

Identifying the white matter pathways involved in multiple sclerosis-related tremor using diffusion tensor imaging

por Bayoumi, Ahmed, Hasan, Khader M., Patino, Jorge, Keser, Zafer, Thomas, Joseph A., Gabr, Refaat E., Pedroza, Claudia, Kamali, Arash, Schiess, Mya C., Wolinsky, Jerry S., Lincoln, John A.
Publicado 2023